Name

Actym Therapeutics, Inc.

Legal name

Actym Therapeutics

Website

https://actymthera.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Immuno-Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Immuno-oncology therapeutics
• Bacterial cancer therapy
• Solid tumor treatment
• Clinical stage biopharmaceutical
• Biologic drug development

Headquarters

HQ city

Berkeley

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue clinical stage company developing novel cancer therapeutics. Revenue will be generated through commercialization of drug candidates upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Actym Therapeutics is a clinical-stage biopharmaceutical company developing the proprietary STACT platform, an engineered Salmonella Typhimurium bacterial vehicle that systemically delivers multiple therapeutic payloads to the tumor microenvironment for immune reactivation. Its lead candidate ACTM-838, delivering IL-15plex and eSTING payloads, is currently in a Phase 1a/1b clinical trial for patients with advanced solid tumors.

Product overview

Actym Therapeutics is a clinical-stage biopharmaceutical company that has developed a proprietary novel drug modality, the STACT™ (S. Typhimurium-Attenuated Cancer Therapy) platform, which harnesses the power of a genetically modified bacterial vehicle designed to safely deliver multiple therapeutic payloads systemically. The company's lead product candidate, ACTM-838, is the first drug based on the STACT™ platform to enter clinical development. ACTM-838 delivers two immune-activating payloads (IL-15plex and eSTING) to tumors, designed to treat solid tumors through immune reactivation. The platform's modular design allows for creation of multiple novel therapies with capacity for multiple payloads, with potential applications beyond oncology including fibrosis.

Differentiator

Problem solved

Functional benefit

Brands

• STACT: S. Typhimurium-Attenuated Cancer Therapy platform - a precisely engineered bacterial delivery vehicle designed for systemic administration to deliver therapeutic payloads locally at disease sites for cancer treatment.

Products and services

• STACT™ Platform Proprietary STACT (S. Typhimurium-Attenuated Cancer Therapy) platform: a precisely engineered bacterial delivery vehicle designed for safe systemic administration that delivers multiple therapeutic payloads amplified and produced locally at the disease site, avoiding systemic toxicity. The modular platform can be tuned to target and proliferate within diseased tissues beyond cancer.
• ACTM-838 ACTM-838 is Actym's lead clinical asset utilizing the STACT platform to deliver two immune-activating payloads (IL-15plex and eSTING) specifically to tumor-resident phagocytic antigen-presenting cells in the tumor microenvironment. It is currently in a Phase 1a/1b clinical trial for patients with advanced solid tumors who have failed prior lines of therapy.

Quantifiable outcome

• Demonstrated reprogramming of tumor immune state and eradication of solid tumors in preclinical studies
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Candel Therapeutics: Candel Therapeutics develops viral immunotherapies for solid tumors (e.g., CAN-2409), using engineered vectors to deliver therapeutic payloads to the tumor microenvironment. Directly comparable to Actym's STACT platform in modality concept (engineered microbial vector for cancer immunotherapy) and clinical stage (Phase 2/3).
• Synlogic: Synlogic develops engineered probiotic (synthetic biology) therapeutics for serious diseases. Directly comparable to Actym in using engineered bacterial chassis as a therapeutic modality, though Synlogic's lead programs target metabolic and inflammatory diseases rather than oncology.
• Locus Biosciences: Locus Biosciences develops engineered bacteriophage therapies targeting bacterial infections and has expanded into oncology applications. Shares Actym's modality of engineered microbial therapeutics and clinical-stage development profile.
• Werewolf Therapeutics: Werewolf Therapeutics develops INDUKINE prodrugs that are selectively activated in the tumor microenvironment to deliver immune-stimulating payloads. Similar to Actym's STACT in using tumor-selective mechanisms to deliver potent IO payloads while limiting systemic toxicity; comparable clinical stage.
• Iovance Biotherapeutics: Iovance commercializes tumor-infiltrating lymphocyte (TIL) therapy for advanced solid tumors, addressing similar refractory solid tumor populations targeted by ACTM-838. Closely comparable patient population and clinical positioning, though with a cell therapy rather than bacterial modality.

Emerging players

• BioAtla: BioAtla develops Conditionally Active Biologics (CABs) for solid tumors, using tumor microenvironment-specific activation similar in concept to Actym's tumor-targeted payload delivery. Both are clinical-stage oncology companies targeting immune-excluded solid tumors.
• Atreca: Atreca is a clinical-stage immuno-oncology company developing antibody-based therapeutics identified from active immune responses. Compares to Actym as a similarly-sized, clinical-stage cancer immunotherapy company focused on novel mechanisms.

Broad incumbents

• BioNTech: BioNTech has a broad cancer immunotherapy pipeline including mRNA cancer vaccines and IO combinations. While a much larger and more diversified player, BioNTech is thematically comparable as a leading developer of cancer immunotherapies targeting solid tumors.
• Moderna: Moderna has an active oncology pipeline including mRNA cancer vaccines (e.g., mRNA-4157) and IO therapeutics. As a large, established biotech with a cancer immunotherapy pipeline, Moderna represents a broader incumbent player in the same therapeutic space.
• Agenus: Agenus is a clinical-stage immuno-oncology company with a broad pipeline of antibodies, vaccines, and cell therapies targeting solid tumors. Comparable as an established IO developer, though with a more diversified modality portfolio than Actym's focused bacterial platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/actym-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actym Therapeutics, Inc.